Peer-reviewedCC BY 4.0Frontiers in Immunology
Editorial: Advances in immunogenicity risk assessment, monitoring and mitigation of biologics
4 affiliations
- 1Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc
- 2Thimmus, LLC
- 3INSERM UMR 996, Universite Paris-Saclay
- 4Quasor
Related
- Editorial: BCIs for monitoring and treating mental health conditions
- Clinical immunogenicity assessment of HIV/AIDS vaccines: current progress and future perspectives.
- IoT-enabled individual poultry monitoring with lightweight step-counting for health assessment
- Explainable plant disease classification and severity assessment using MobileNetV3-large for crop health monitoring
- Do Botanical Gardens Pose a Pollen Allergenicity Risk? A Multi-Method Assessment Integrating Species-Specific Values of Potential Allergenicity and Pollen Concentration Monitoring
BibTeX
@article{tourdot2026editorial,
title = {{Editorial: Advances in immunogenicity risk assessment, monitoring and mitigation of biologics}},
author = {Sophie Tourdot and Daniela Verthelyi and Marc Pallardy and Timothy Paul Hickling},
journal = {Frontiers in Immunology},
year = {2026},
month = sep,
doi = {10.3389/fimmu.2026.1979026},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1979026/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Editorial: Advances in immunogenicity risk assessment, monitoring and mitigation of biologics
AU - Sophie Tourdot
AU - Daniela Verthelyi
AU - Marc Pallardy
AU - Timothy Paul Hickling
PY - 2026
DA - 2026/09/30
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1979026
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1979026/full
SN - 1664-3224
ER -